Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia - Contacts and Locations

Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia

This study has been completed.

Study NCT00066326. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00066326

Locations


United States, California
	City of Hope Comprehensive Cancer Center
	Duarte, California, United States, 91010-3000
	City of Hope Medical Group
	Pasadena, California, United States, 91105
	University of California Davis Cancer Center
	Sacramento, California, United States, 95817
	USC/Norris Comprehensive Cancer Center and Hospital
	Los Angeles, California, United States, 90089

United States, Maryland
	Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
	Bethesda, Maryland, United States, 20892-1182

United States, Michigan
	Barbara Ann Karmanos Cancer Institute
	Detroit, Michigan, United States, 48201-1379

United States, Ohio
	Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
	Columbus, Ohio, United States, 43210-1240

United States, Pennsylvania
	Hillman Cancer Center at University of Pittsburgh Cancer Institute
	Pittsburgh, Pennsylvania, United States, 15213-1863

Sponsors and Collaborators

Barbara Ann Karmanos Cancer Institute

National Cancer Institute (NCI)

Investigators


Study Chair:	Charles A. Schiffer, MD	Barbara Ann Karmanos Cancer Institute